Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Stocks to buy: Piramal Pharma, HSCL among 3 top bets by Choice Broking
Stocks to buy: Here's why Aakash Shah, technical analyst at Choice Broking recommends a 'Buy' on Piramal, Aza Engineering and Himadri Speciality Chemical this week.
After Nestle, FSSAI Issues Notices To Eight Brands For Misleading Trade Names, Healthy Claims — Check Full List
FSSAI has issued notices to Emami Healthy & Tasty, Health Aid, Troovy, The Healthy Factory, Healthy Master, Healthy Choice, Plan B and Neuherbs.
Choice reiterates 'Buy' on Jeena Sikho, sees 44% upside; stock rises 20%
Analysts Deepika Murarka and Stuti Bagadia expect JSLL to deliver revenue, Ebitda and PAT CAGR of 33.6 per cent, 34.9 per cent and 41.6 per cent, respectively, over FY26-FY29E
Stocks to buy today: Sudeep Pharma, Rubicon Research, ICICI Prudential AMC
Stocks to buy today: Aakash Shah of Choice Broking has recommended buying three stocks today - Rubicon Research, Sudeep Pharma, and ICICI Prudential Asset Management.
Park Medi World share: Choice sees over 20% upside despite 90% YTD return. Should you buy?
Park Medi World shares, up 90% YTD, could rise another 20% to ₹350, supported by significant capacity expansion and improved financial performance, including a 30% revenue increase.
Top trading ideas: Analyst bets on Yatharth Hospital, RPEL, Ingersoll-Rand
Top trading ideas: Aakash Shah of Choice Equity Broking suggests buying these three stocks today; here's why
Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sector
Bernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future growth for the Indian healthcare sector. Key drivers include AI-led innovation, incremental advancements in niche areas, and improved quality culture. Attractive valuations also support this positive outlook for the industry.
Visa bets on cheaper tech and consumer choice to take on the UPI juggernaut
UPI’s share of India’s digital payments volume rose to 84% in 2025, but the global payments major believes it can stay competitive by benchmarking merchant pricing against domestic rivals and tweaking its unit economics if needed, a top Visa India executive told Mint.
Buy Senores Pharma; target of Rs 1640: Choice Institutional Equities
Choice Institutional Equities is bullish on Senores Pharma has recommended buy rating on the stock with a target price of Rs 1640 in its research report dated July 08, 2026.
Buy Park Medi World; target of Rs 320: Choice Institutional Equities
Choice Institutional Equities is bullish on Park Medi World has recommended buy rating on the stock with a target price of Rs 320 in its research report dated April 30, 2026.